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The renin-angiotensin system (RAS), a key regulator of the blood pressure and ﬂuid/electrolyte homeostasis, also plays a critical
role in kidney development. All the components of the RAS are expressed in the developing metanephros. Moreover, mutations
in the genes encoding components of the RAS in mice or humans are associated with a broad spectrum of congenital anomalies
of the kidney and urinary tract (CAKUT). These forms of CAKUT include renal papillary hypoplasia, hydronephrosis, duplicated
collecting system, renal tubular dysgenesis, renal vascular abnormalities, and aberrant glomerulogenesis. Emerging evidence
indicates that (pro)renin receptor (PRR), a novel component of the RAS, is essential for proper kidney development and that
aberrant PRR signaling is causally linked to cardiovascular and renal disease. This paper describes the role of the RAS in kidney
development and highlights emerging insights into the cellular and molecular mechanisms by which the PRR may regulate this
critical morphogenetic process.
1.Introduction
1.1. Brief Overview of Kidney Development. During embryo-
genesis, the nephric duct (ND) is formed from the interme-
diate mesoderm on embryonic (E) day E22 in humans and
E8 in mice [1]. The ND extends caudally and induces adja-
cent intermediate mesoderm to form two transient kidney
types,pronephrosandmesonephros.Thepronephrosdegen-
erates in mammals, whereas the mesonephros involutes in
females, but gives rise to male reproductive organs [1]. On
5th week of gestation in humans (E10.5 in mice), the caudal
portion of the ND forms an epithelial outgrowth called the
ureteric bud (UB). The metanephric kidney arises from two
embryonictissues: theUBandthemetanephric mesenchyme
(MM)[2,3](Figur es1(a)–1(d)).UBgrowsoutfromtheND,
elongates, invades the MM, and then branches repeatedly
within the mesenchyme to form the renal collecting system
(the ureter, pelvis, calyces, and collecting ducts) [3–5].
Linear arrays of inner (medullary) collecting ducts converge
centrally to form the papilla. Distal ureter subsequently
translocates from the ND to fuse with the bladder which
originates from the urogenital sinus (Figures 1(e)–1(g))
[6, 7]. Terminal UB tips induce surrounding MM-derived
nephron progenitors to condense and then diﬀerentiate into
nephrons (from the glomerulus to the distal tubule), thus
forming the metanephric kidney (Figures 1(a)–1(d)) [3, 4].
1.2. Wnt Signaling in Metanephric Kidney Development. Me-
tanephric kidney development depends on reciprocal inter-
actions of transcription and growth factors expressed in the
metanephric mesenchyme, stroma and the UB [3, 8, 9].
The wingless (Wnts) are secreted glycoproteins fundamen-
tal for proper kidney development. Wnt ligands bind to
extracellular domain of frizzled (Fz) seven trans-membrane
domain receptors and, in some cases, the low-density lipo-
protein (LRP) 5 and 6 coreceptors to activate distinct intra-
cellular signaling cascades [10–12]. Wnt signaling regulates
metanephric kidney development via canonical or nonca-
nonical signaling pathways [13]. Binding of Wnt to its recep-
tor leads to accumulation of β-catenin in the cytoplasm fol-
lowed by translocation to the nucleus and interaction with
theT-cellfactor/lymphoid-enhancing factor(Tcf/Lef)family
oftranscription factorstoregulategenetranscription[14].In
addition, β-catenin is an important component of cell-cell
adherens junctions and interacts with the actin cytoskeleton
[15]. The noncanonical Wnt signaling pathway consists
of the planar cell polarity/convergent extension (PCP/CE)2 International Journal of Nephrology






















Figure 1: Schematic representation of normal development of the kidney and urinary tract. (a): Invasion of the metanephric mesenchyme
(MM)by the ureteric bud (UB) onweeks 5-6 ofgestationinduces MM cells to aggregate around the UB tip. (a)–(c):UB outgrowthfrom the
nephric duct (ND), its subsequent iterative branching (branching morphogenesis), and continuous condensation of the MM cells around
emerging UB tips are induced primarily by reciprocal interactions among glial-derived neurotrophic factor (GDNF), its receptor c-Ret, and
coreceptor GFRα1. (b): MM cell aggregates undergo mesenchymal-to-epithelial transformation (MET) to form the renal vesicle (RV) on
weeks 6–36 of gestation. (c): RV elongates along the proximal-distal axis to form comma-shaped and then S-shaped nephron. Distal ends
of S-shaped nephrons fuse with UB-derived collecting ducts, whereas proximal clefts form glomeruli. Endothelial cells migrate into the
proximal cleft. UB branching occurs on weeks 6–22 of gestation. Formation of nascent nephrons and their patterning occur on weeks 6–36
of gestation. (d): Patterning of the S-shaped nephron and UB result in formation of mature nephron which contains glomerulat capillary
tuft, podocytes, proximal tubule, loopof Henle, distal tubule, and collecting duct. (e). Ureter becomes patent andcommonND (CND) fuses
with cloaca on weeks 4-5 of gestation. (f): Apoptosis of the CND accounts for the positioning of the ureter (derived from proximal UB) in
proximity of the urogenital sinus on weeks 5-6 of gestation. (g): Ureter fuses with the bladder by 6 weeks of gestation (with kind permission
from Springer Science + Business Media: [82]). Please see text for details.
pathway and the Ca2+-releasing pathway [13]. PCP controls
polarization of cells within the plane of the tissue, whereas
CE directs intercalation of cells in an epithelial sheet to
form a longer and narrower strip of the tissue [16]. Sever-
al Wnts are expressed in the discrete domains of the devel-
oping mouse kidney and play a critical role in proper me-
tanephric organogenesis. Wnt6, Wnt7b, Wnt9b, and Wnt11
are expressed in the UB [17–19]. Wnt4 is expressed in the
MM and Wnt2b in the cortical stroma [17, 20]. Of the
Wnts expressed in the metanephros, Wnt2b, Wnt4, Wnt7b,
and Wnt9b activate canonical pathway. Wnt signaling is
essential for UB branching, nephrogenesis, and medullary
patterning. Available data suggest that UB signals to the MM
by secreting Wnt9b, a soluble growth factor, which acts via
the canonical β-catenin to induce expression of ﬁbroblast
growth factor 8 (FGF8), LIM homeobox 1 (Lhx1)a n dWnt4
in the MM [18, 21]. In turn, Wnt4 induces MM cells to
undergo mesenchymal-to-epithelial transformation (MET)
and diﬀerentiate into the nephron epithelia [21]. Genetic
inactivation of Wnt9b or Wnt4 in mice leads to arrest of
nephrogenesis at renal vesicle stage, and deﬁciency of Wnt9b
causes severe defects in UB branching [18, 21]. UB-speciﬁc
inactivationofβ-catenin, thecentraleﬀectorof thecanonical
Wnt signaling pathway, causes aberrant UB branching and
premature diﬀerentiation of collecting duct cells and results
in renal hypodysplasia [22, 23]. In addition to directing
UB branching and nephrogenesis via the canonical pathway,
Wnt9b acts via a noncanonical Wnt pathway to induce PCP
in UB-derived collecting ducts. Available evidence suggests
that longitudinally oriented cell division (OCD) leads to
collecting duct elongation without a change in diameter. In
conditionsin which collectingductsdilatetoformcysts(e.g.,
polycystic kidney disease), OCD is randomized, leading to a
progressive increase in collecting duct diameter [24]. Mice
that lack Wnt9b exhibit dilated collecting ducts, aberrant
OCD of the collecting duct cells and develop renal cysts
postnatally [25]. Wnt7b-mutant mice do not form renal
medulla and papilla [26]. These defects are likely due to
aberrant OCD and decreased survival of the medullary
collecting duct cells [26].
2.The Renin-AngiotensinSystem
The renin-angiotensin system (RAS) plays a fundamen-






























Figure 2: The Renin-Angiotensin System. Ang: angiotensin II. ACE: angiotensin-convertin enzyme, ACE2: angiotensin-converting enzyme
2, AMPA: aminopeptidase A. Please see text for details.
ﬂuid/electrolyte homeostasis, and kidney development [27].
In the RAS,renin cleavesangiotensinogen (AGT) to generate
Ang I [Ang-(1–10)] (Figure 2). Ang I is converted by angi-
otensin-convertingenzyme(ACE)toAngII[Ang-(1–8)],the
most powerful eﬀector peptide hormone of the RAS [28–
30]. Ang II acts via two major G protein-coupled receptors
(GPCR): AT1Ra n dA T 2R[ 29]. Most of hypertensinogenic
and sodium-retaining actions of Ang II are attributed to
the AT1R[ 31]. In contrast to the AT1R, the AT2Re l i c i t s
vasodilation, promotes renal sodium excretion, and inhibits
proliferation in mesangial cells [32–34]. ACE2 is a homo-
logue of ACE which is abundantly expressed in the kidney
and acts to counterbalance ACE activity by promoting Ang
II degradation to the vasodilator peptide Ang-(1–7) [35, 36].
Ang-(1–7) acts via the GPCR Mas encoded by Mas pro-
tooncogenetoopposeAngII-AT1R-mediated eﬀects[37,38].
Renin is synthesized in juxtaglomerular cells of the aﬀerent
arterioles of the kidney as preprorenin [39]. The human
renin gene encoding preprorenin is located on chromosome
1[ 40]. Cleavageof a 23amino acid signal peptideat carboxyl
terminus ofpreproreningeneratesprorenin. Proreninis then
converted to active renin by cleavage of 43-amino acid
N-terminal prosegment by proteases [41, 42]. The kidney
secretes both renin and prorenin into the peripheral circu-
lation. Plasma levels of prorenin are approximately 10-fold
higher than those of renin [43].
In addition to cleaving AGT, renin binds the (pro)renin
receptor (PRR) [44, 45]. The PRR protein is a seven trans-
membrane domain receptor encoded for by the ATP6AP2
(ATPase-associated protein2)/PRR gene (subsequently referred
to as PRR) located on the X chromosome in humans [44].
The PRR protein exists in three forms: (1) A full-length
35–39kDa form composed of 3 domains: extracellular, a
single transmembrane, and a cytoplasmic, (2) A 28kDa
solubleform found in plasma and urine, and (3)A truncated
form containing transmembrane and cytoplasmic domains
[42, 45]. In addition to proteolytic activation via cleavage of
the prosegment by proteases, prorenin may be activated by
bindingtothePRRandundergoingaconformationalchange
that does not require removal of the prosegment [44].
2.1. Expression of the RAS Components in the Developing
Metanephros. The developing metanephros expresses all
the components of the RAS [46–48]. In the fetal mouse
kidney, renin mRNA is ﬁrst detected on E14.5 by in situ
hybridization in a few scattered foci of cells [46]. By E15.5,
renin is widely expressed in branches of the renal artery,
interlobar, and arcuate arteries. In the human kidney, renin
mRNA is detected at the vascular pole of the glomerulus
and in arteries located next to glomeruli [48]. With fetal
maturation, renin expression shifts to its mature localization
inthejuxtaglomerularcells[46,48].Studiesinreninknockin4 International Journal of Nephrology
reporter mice have demonstrated that renin-producing cells
may originate from the mesenchyme at E11-E12 before
vesseldevelopmenthasoccurred[49].Ontogenystudieshave
demonstrated that renal renin synthesis is highly activated
during early postnatal development in rodents [47]. Because
immunoreactive Ang II levels are higher in the fetal and
newborn than adult mouse kidney [50, 51], renin is con-
sidered to be the rate-limiting factor for Ang II generation
during metanephric development. In the adult rat kidney,
PRR mRNA and protein are expressed in the collecting
duct and the distal nephron [52]. In the CD, the PRR is
most abundant at the apical surface of type A intercalated
cells where it colocalizes with the vacuolar H+-ATPase [52].
In addition, PRR immunoreactivity is also detected in the
podocytes, renal mesangial, vascular smooth muscle, and
endothelial cells [53–55]. Even though PRR is expressed in
Xenopuspronephros[56],theexpressionofthePRRgeneand
PRRprotein during metanephric developmentremains to be
determined.
2.2. Eﬀect of Pharmacological or Genetic Interruption of the
RAS on Kidney Development. Treatment of several animal
species or humans with ACE inhibitors or AT1Ra n t a g o n i s t s
during gestation or postnatal metanephrogenesis leads to
renal tissue dysplasia [57]. A decrease in the number and
size of glomeruli, delay in glomerulogenesis, a reduction in
the number and length of the renal arteries accompanied by
arterial thickening,tubulardilation and a hypoplastic papilla
are observed [58]. Nephrotoxic eﬀects of ACE inhibitors
and AT1R antagonists in humans include oligohydramnios
and anuria [59, 60]. AGT-, renin-, ACE-, or AT1R-deﬁcient
mice exhibit virtually identical phenotypes characterized by
vascular hyperplasia, hydronephrosis, hypoplastic medulla,
and papilla [61–66]. Functionally, Renin-, ACE-, and AT1R-
null animals are polyuric and have a reduced ability to
concentrate urine [63–65]. Deletion of the AT2R in mice
causesectopicUBbuddingfromthenephricduct,duplicated
collecting systems, and hydronephrosis [67]. Mutations in
the genes encoding for AGT, renin, ACE, or AT1R in humans
are associated with renal tubular dysgenesis (RTD) [68,
69]. Kidneys of patients with RTD demonstrate reduced
number of proximal tubules, collapsed collecting ducts,
enlarged glomeruli, and thickened arteries [69]. Attempts
to generate knockout mice with global deletion of the Prr
failed [70]. Even though this observation precludes so far
determination of the speciﬁc role for the PRR in kidney
organogenesis, it also indicates that the PRR is essential
during development. Targeted inactivation of the Prr gene
in mouse cardiomyocytes causes cardiac tissue ﬁbrosis,
cardiomyocyte apoptosis, and death within the ﬁrst several
weeks of postnatal life from heart failure [71].
2.3.Signaling PathwaysDownstreamofthePRR. Eventhough
the cytoplasmic domain of the PRR has no intrinsic kinase
activity [48], in vitro studies demonstrate that binding of the
PRR by renin or prorenin leads to activation of mitogen-
activated protein (MAP) kinases such as Erk1/2 or p38
in renal mesangial and vascular smooth muscle (VSMC)
cells and induces phosphorylation of phosphatidylinosi-
tol 3-kinase/Akt (PI3K/Akt) in human embryonic kidney
(HEK293T) cells [72, 73]. The eﬀect of the PRR on Erk1/2
phosphorylation in human monocytes is independent of
Ang II or transactivation of the EGF receptor [74]. In
contrast, induction of Erk1/2 and Akt phosphorylation
by recombinant rat prorenin in cultured rat VSMCs is
independent of Ang II, but dependent on phosphorylation
of EGF receptor [75]. Since these changes are blocked by
the PRR siRNA, activation of the EGF receptor, Erk1/2, and
Akt in VSMC depends on PRR. The importance of the
PRR-dependent Erk1/2 activation in brain development is
evident from the observations that hypomorphic mutation
in the PRR is causally linked to the absence of Erk1/2
phosphorylation and the development of X-linked mental
retardation in humans [76].
2.4. Role of the PRR in Kidney and Cardiovascular Disease.
A direct pathological role of the PRR in renal injury
and cardiovascular disease is suggested by the ﬁndings of
glomerulosclerosis, proteinuria, and elevated blood pressure
in rats with ubiquitous transgenic overexpression of the
human PRR (Table 1)[ 91]. Targeted overexpression of the
Prr in the rat vasculature under the control of the mouse
smooth muscle myosin heavy chain gene causes mild hyper-
tension after six months of age [77]. Although transgenic
overexpression of the prorenin, a major ligand for the PRR,
in rats does not cause renal ﬁbrosis, it leads to myocardial
hypertrophy, proteinuria, and hypertension [92, 93]. Of
interest, since hypertension is controlled by ACE inhibition,
it may be due to the increased formation of Ang II [92, 93].
Double-transgenic mice that overexpress human prorenin in
the liver and human angiotensinogen in the heart display
a selective increase in Ang I content in the heart (but not
the plasma) as compared to the single-transgenic mice [94].
These results suggest that circulating prorenin is taken up by
tissues where it can contribute to the local synthesis of Ang
peptides and tissue damage. Expression of the PRR mRNA
and protein is increased in the myocardium and renal tubu-
lar, VSMC, and endothelial cells in rats with congestive heart
failure due to coronary ligation [54]. Moreover, treatment
of spontaneously hypertensive rats (SHRs) with a synthetic
peptide that blocks prorenin binding to the PRR reduces
renal and cardiac ﬁbrosis [78, 95]. These data demonstrate
that the PRR may contribute to the pathogenesis of heart
failure and kidney tissue damage. An important role for
the PRR in the pathogenesis of hypertension in humans
is supported by the ﬁndings that a polymorphism in the
PRR gene is associated with a high blood pressure in men
(IVS5+169C>T) and left ventricular hypertrophy in women
(+1513A>G) [80, 81].
Although rare cases of human hypertension or CAKUT
are due to mutations in single genes, the contribution of the
genetic determinants in the vast majority of subjects with
high blood pressure or CAKUT remains unknown [82, 96].
If common diseases such as hypertension or nonsyndromic
cases of CAKUT are due to multiple gene variants with small
eﬀects, large study samples are needed to identify them.International Journal of Nephrology 5
Table 1: Role of (pro)renin receptor (PRR) signalingin kidney development and disease.
Model Renal phenotype Cardiovascular phenotype Other phenotype References
Global overexpression of human
PRR in the rat
Glomerulosclerosis
Proteinuria Elevated blood pressure Unknown [54]
Targeted overexpression of human
PRR in rat vasculature Unknown Elevated blood pressure and heart
rate Unknown [77]
SHR rats treated with PRR blocker Attenuation of
renal ﬁbrosis Attenuation of cardiac ﬁbrosis Unknown [78]
Mice with targeted deletion of Prr
in cardiomyocytes Unknown Cardiac tissue Fibrosis
Cardiomyocyt opoptosis Unknown [71]
Xenopus embryos treated with
anti-PRR morpholino Unknown Unknown
Short body axis Impaired CE
Small head
Short tail
Defects in eye pigmentation
[79]
[56]
Genetic polymorphism of PRR in




Hypomorphic PRR mutations in
humans Unknown Unknown X-linked mental retardation
Epilepsy [76]
SHR: spontaneously hypertensive rats, CE: convergent extension, LVH: left ventricular hypertrophy, PRR: human PRR gene, PRR: human PRR protein, Prr:
mouse PRR gene.
Within the last few years, several genome-wide association
studies (GWAS), in which thousands of common genetic
variants are analyzed for disease association, identiﬁed
signiﬁcant association of a limited number of genes with
primary hypertension [97]. Further studies are needed to
understand how the implicated genes contribute to such
a complex multifactorial disease as primary hypertension.
Despite identiﬁcation of signiﬁcant association of hyperten-
sion with variants of renin, ACE and AGTR1 genes in a study
by Zhu et al. [98], the results of RAS gene-association
studies are inconsistent [99]. With respect to CAKUT, broad
phenotypic spectrum of renal system anomalies and vari-
ability in genotype-phenotype correlation demonstrate that
pathogenesis of CAKUT is a complex process that depends
on interplay of many factors [82, 100]. It is likely that well-
powered studies utilizing total human exome capture and
next-generation sequencing will identify single-gene defects
leading to CAKUT.
2.5. Potential Roles for the PRR in Kidney Development.
T h em e c h a n i s m sb yw h i c ht h eP R Rm a yr e g u l a t ek i d n e y
development may involve changes in the expression of genes
or transcription factors that are critical for metanephric
organogenesis, physical interaction between the PRR and
other receptors or proteins with established roles in renal
ontogenyorfunction, activation oftheintracellular signaling
pathways, or other mechanisms (Figure 3).
2.5.1. Interaction with the Promyelocytic Zinc Finger Tran-
scription Factor (PLZF). PLZF is a nuclear phosphoprotein
which belongstothe POZ/zinc-ﬁnger family of transcription
factors and is encoded by the Zfp145 gene. Zfp145-null mice
exhibit aberrant expression of Hox genes, defects in limb,
and axial skeletal patterning, whereas the kidney phenotype
of these mice was not described [101]. Several observations
support potential role for PLZF in kidney development. For
example, Hox (Hox11) genes are necessary to specify the
metanephric kidney identity from the intermediate meso-
derm [102]. In patients with acute promyelocytic leukemia,
PLZF fuses with the retinoic acid receptor α (RARα)a n d
recruits histone deacetylase 1 (HDAC1) to render retinoic
acid-target genes unresponsive to retinoic acid, an active
form of vitamin A [103]. Both HDAC1 and retinoic acid are
essential for embryo development. Genetic inactivation of
HDAC1 in mice results in embryonic lethality before E10.5
due to severe proliferation defects [104], whereas RAR-
mutant mice display renal dysplasia [105]. Concerning the
RAS, inhibition of HDAC activity induces renin expression
in the embryonic kidney [106, 107]. PRR interacts with the
PLZF protein in HEK293 cells in vitro [73]. Moreover,
treatment of HEK293 cells with renin causes nuclear trans-
location of PLZF followed by recruitment of PLZF to the
promoters of the PRR and PI3K-p85α genes. This leads
to repression of PRR transcription and induction of PI3K
gene expression [73]. Notably, inhibition of PI3K/Aktblocks
UB branching induced by glial-derived neurotrophic fac-
tor (GDNF)/rearranged during transfection (Ret) ligand-
receptor pair or by Ang II [85, 86].
In addition, PLZF inhibits transcription of c-kit in
CD34+ hematopoietic progenitor cells (HPC) and in sper-
matogonia [83, 108]. Functionally, increased c-kit expression
is necessary to sustain diﬀerentiation of these cells. Zfp145-
null mice exhibit depletion of the proliferative spermatogo-
nial compartment in the testis due to deregulated expression
of c-kit, which controls a tight balance between spermatogo-
nial self-renewal and diﬀerentiation [108]. c-kit is a receptor
tyrosine kinase (RTK) for the stem cell factor (SCF), a key
regulator of HPC proliferation, survival, and diﬀerentiation
[83]. Notably, c-kit is expressed in the interstitial cell and
angioblasts of the developing metanephros [84]. Moreover,
antagonism of c-kit RTK activity inhibits UB branching and
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Figure 3: Proposed mechanisms mediating the eﬀect of the (pro)renin receptor (PRR) in metanephric kidney development. (a): PRR
interacts with Wnt receptor frizzled (Fz) to regulate polarization and intercalation of collecting duct (CD) cells via planar cell polarity
(PCP)/convergent extension (CE) Wnt signaling pathway [16, 25, 79]. (b): PRR may regulate UB branching by (1) inhibiting c-kit
transcription via promyelocytic zinc ﬁnger transcription factor (PLZF) [73, 83, 84] (2) induction of Erk1/2, PI3K/Akt or epidermal growth
factor receptor (EGFR) phosphorylation [52, 72, 73, 75, 85–87], and (3) interaction with LRP5/6 Wnt coreceptor leading to activation of
β-catenin and Ret gene expression [22, 23, 56]. (c): PRR interacts with LRP5/6 and V-ATPase to form a complex at the plasma membrane.
Following endocytosis, V-ATPase generates a gradient of H+ ions that is essential for LRP5/6 phosphorylation and activation of β-catenin
[56]. V-ATPase stimulates Notch signaling [88]. Notch acts to deﬁne the podocyte and proximal tubular cell fates [89]a n dr e g u l a t e s
diﬀerentiation of the CD cells [90].
Since PLZF represses c-kit expression, loss of PLZF can cause
dysregulation of the diﬀerentiation of c-kit-positive progeni-
tors of renal interstitial cells and lead to renal hypodysplasia.
2.5.2. Interactions with the Canonical Wnt/β-Catenin Sig-
naling. Another mechanism by which the PRR may con-
trol metanephric development is by the regulation of the
canonical Wnt/β-catenin signaling. Inhibition of the PRR
by small inhibitory RNA (siRNA) in HEK293T cells in vitro
or by the PRR antisense morpholino in Xenopus embryos
in vivo decreases luciferase reporter activity stimulated by
canonical Wnt signaling [56]. The PRR binds to Fz8 and
LRP6 in HEK293T cells transfected with the PRR expression
vector. Activation of LRP6 and β-catenin signaling depends
on extracellular, but not on cytoplasmic or transmembrane,
domain of the PRR [56]. Given that canonical Wnt signaling
is critical in metanephric organogenesis [22, 23], it is con-
ceivable that direct interaction between the PRR and LRP6
plays an important role in the activation of canonical Wnt
signaling viaβ-catenin to regulate kidney development.This
possibility is supported by the observations that mutations
in LRP4, which is known to antagonize LRP6-mediated
activation of canonical Wnt signaling, are associated with
CAKUT in humans with Cenani-Lenz syndrome (OMIM#
604270) [109].
2.5.3. Interactions with Noncanonical Wnt/PCP Signaling. In
addition to its function in canonical Wnt signaling, PRR
modulates Wnt/PCP pathway of the noncanonical Wnt
signaling. Treatment of Xenopus embryos with anti-PRR
morpholinos causes a short body axis and a broader ex-
pression domain of the notochord marker Xnot,ah a l l m a r k
of impaired convergentextension movements [79]. Aberrant
convergent extension (lateral intercalation) of the collecting
duct and renal tubular cells may be causally linked to
polycystic kidney disease [25]. In addition, Drosophila PRR
interacts biochemically with Fz in HEK293T cells [79]. The
Drosophila Fz receptor is required for PCP. Collectively,
PRR mediates both the Wnt/PCP and the Wnt/β-catenin
signaling pathways. These eﬀectsofthe PRRare independent
of renin [56, 79].
2.5.4. Interactions with V-ATPase. PRR may regulate kidney
development or function via the V-ATPase (Figure 3). V-
ATPase is a multiprotein complex localized in the kidney
in intracellular organelles and at the plasma membrane of
the intercalated collecting duct cells. Its major function is
to pump protons to promote endocytosis [110]. Mutations
in the genes encoding the kidney-speciﬁc isoforms B1 or
A4 of V-ATPase in humans are responsible for inheritable
forms of distal renal tubular acidosis, a disease characterized
by elevated H+ concentrations in the plasma due to the
impaired renal excretion of acid [111, 112]. Critical role for
V-ATPase in development is evident from the observation
that mutations in the genes encoding subunits C or D of
V-ATPase in mice result in embryonic lethality [113, 114].
Mutations in subunits B1 or A3 of V-ATPase in mice cause
metabolic acidosis and osteopetrosis, respectively [115, 116].
Variability in defects observed in these mice indicates that
diﬀerent subunits of V-ATPase have diﬀerent functions and
that subunits A3, A4, and B1 may be important in boneInternational Journal of Nephrology 7
remodelingordiﬀerentiationofcollectingductcellsinvolved
in acid-base homeostasis.
In vitro studies demonstrate that the endogenous PRR
binds to the endogenous V-ATPase subunits ATP6V0D1 and
ATP6V0C in HEK293T cells [56]. Injection of a dominant-
negative V-ATPase subunit E in Xenopus embryos synergizes
with anti-PRR morpholino in inhibition of Wnt signaling.
Phosphorylation of LRP6, which correlates with LRP6 acti-
vation, is inhibited in mouse P19 embryonal carcinoma cells
treated with PRR-o rV-ATPase siRNA [56]. These ﬁndings
indicate that the PRR and V-ATPase interact functionally to
inhibit Wnt signaling during Xenopus embryonic develop-
ment in vivo.
Genetic inactivation of the Prr in cardiomyocytes in
mice decreases expression of the V(O) subunits of V-ATPase,
resulting in deacidiﬁcation of the intracellular vesicles [71].
Thus, the PRR is also essential for vacuolar H+-ATPase
assembly in murine cardiomyocytes in vivo. Mutations in
VhaAC39, a V-ATPase subunit, in Drosophila are associated
with the loss of Notch signaling [88]. Ligand binding to
Notchreceptorinducesproteolyticcleavageandreleaseofthe
intracellular domain of Notch which enters the cell nucleus
to regulate target gene expression. Notch signaling exerts
dual function during mouse metanephric development.
Notch activity deﬁnes the podocyte and proximal tubular
cell fates during segmentation of the S-shaped body [89].
In the collecting duct, Notch acts to increase the ratio of
principal-to-intercalated cells and regulate urinary concen-
trating ability [90]. Thus, Notch signaling is required for the
diﬀerentiation and functional maturation of the principal
cells in murine renal collecting duct. Mutations in Notch2 in
humans result in Alagille syndrome (OMIM# 610205)[117].
The renal phenotype in Alagille syndrome is characterized
by hypodysplasia. Since PRR is most abundant at the apical
surface of type A intercalated cells of the collecting duct,
where it colocalizes with the vacuolar H+-ATPase, in the rat
[52], the PRR may act in an autocrine fashion to regulate
H+ transport. During metanephric development, PRR may
promote diﬀerentiation of H+-secreting intercalated cells in
the collecting duct. PRR located on the apical membrane of
intercalated cells may be activated in a paracrine fashion by
prorenin released by adjacent principal cells [118]. Addition-
al evidence to implicate regulated intracellular acidiﬁcation
in mediating Wnt signaling is provided by the observations
that Nhe2, a sodium/proton exchanger in Drosophila and
a homologue to human NHE3, interacts genetically with
Fz receptor to regulate Wnt/PCP signaling [119]. Together,
these ﬁndings suggest that PRR cross-talks with V-ATPase
in a renin-independent fashion to regulate both canonical
Wnt/β-catenin and noncanonical Wnt/PCP signaling.
2.5.5. Regulation of Intracellular Signaling Pathways Critical
for Metanephric Kidney Development. Another mechanism
by which the PRR may modulate metanephric morphogen-
esis is via activation of downstream signaling pathways such
as PI3K or Erk1/2 [72, 73]. This possibility is supported by
an attenuation of Erk1/2 phosphorylation with PRR siRNA
in collecting duct/distal tubule lineage Madin-Darby Canine
Kidney (MDCK) cells in vitro [52]. An important role for
Erk1/2 and PI3K in kidney development is demonstrated
by the ﬁndings that inhibition of Erk1/2 decreases UB
branching [120] and that antagonism of PI3K/Akt blocks
directional migration of Ret-transfected MDCK cells in
response to GDNF in vitro [85]. Critical role of GDNF and
Ret in UB morphogenesis is evident from the ﬁndings that
targeted inactivation of GDNF or Ret in mice results most
frequently in bilateral renal agenesis due to a failure of UB
outgrowth [121, 122]. Notably, tyrosine phosphorylation of
the EGF receptor and activation of PI3K/Akt and Erk1/2
are also essential for Ang II-induced UB branching [86,
87].
3.ConclusionsandPerspectives
The PRR is emerging as potential critical player in normal
metanephric kidneydevelopment.Ithasbecomeevidentthat
the PRR has an evolutionary conserved role in bridging V-
ATPases with canonical and noncanonical Wnt signaling.
Acting viathese or other intracellular pathways (e.g., Erk1/2,
PI3K), the PRR may regulate segmentation of the proximal
nephron and direct functional maturation of UB-derived
collecting ducts. Even though signiﬁcant progress has been
made in deﬁning the potential role of the PRR and spe-
ciﬁc contribution of PRR-dependent signal transduction in
metanephric development, further evidence supporting the
direct role for the PRR in metanephric organogenesis is
needed.Whataretheperspectivesforsystem-wideapproach-
estounderstandtheroleofthePRRinkidneyorganogenesis?
In this regard, application of new genetic tools, such as
conditional/tissue/cell-speciﬁc gene knockouts, genetic lin-
eage tracing and ﬂuorescent in vivo reporters of cell sig-
naling, genome-wide analysis of gene regulatory networks
(including epigenetic regulation) that control diﬀerent as-
pects of kidney development (e.g., microarray, ChIP-Seq)
should provide important insights in understanding molec-
ular mechanisms by which the PRR may direct normal
and abnormal metanephric kidney development. Deﬁning
molecular aberrations leading to CAKUT in animals and
humans with mutations in the PRR will uncover biomarkers
that can be used for early diagnosis or prevention of
renal system anomalies in children. Finally, establishment of
shared large biorepositories of patients encompassing a wide
spectrum of CAKUT phenotypes for molecular, genetic, and
translational studies will deﬁne clinically relevant mutations
in the PRR, its ligands, and interacting genes. The evolution
of our understanding of the cellular and molecular mech-
anisms by which intact PRR controls metanephric kidney
development may provide targets for improved diagnosis
and prevention of CAKUT in children.
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